CN108866200A - Carcinoma of mouth diagnosis marker and its application - Google Patents
Carcinoma of mouth diagnosis marker and its application Download PDFInfo
- Publication number
- CN108866200A CN108866200A CN201811172243.8A CN201811172243A CN108866200A CN 108866200 A CN108866200 A CN 108866200A CN 201811172243 A CN201811172243 A CN 201811172243A CN 108866200 A CN108866200 A CN 108866200A
- Authority
- CN
- China
- Prior art keywords
- carcinoma
- mouth
- marker
- oral cavity
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
The invention discloses a kind of carcinoma of mouth diagnosis marker and its applications, and the nucleotide probe sequences of the marker are respectively as shown in SEQ ID NO.1-SEQ ID NO.20.This kind of marker can individually or two or more is combined to carry out the diagnosis of carcinoma of mouth.Totally 20 kinds of oral cavity carcinoma marker provided by the invention, there is the characteristics of accuracy is high, high sensitivity, significantly increase wherein 8 kinds of markers are expressed in the cancerous tissue of oral cavity compared to normal group, 12 kinds of markers are expressed in the cancerous tissue of oral cavity to be significantly reduced compared to normal group.Area (AUC) is all larger than 0.9 under all 20 kinds of marker prediction curves, its accuracy and susceptibility is prompted to reach 90% or more.Wherein the AUC of ADAM12, CAB39L, COL10A1 and HLF are greater than 0.95, can be directly used as the diagnosis of carcinoma of mouth.
Description
Technical field
The invention belongs to biomedicine fields, specifically, being related to a kind of carcinoma of mouth diagnosis marker and its application.
Background technique
Carcinoma of mouth (Oral Cavity Cancer) is the 6th kinds of tumor of whole body, and 90% or more oral cavity and oropharynx are pernicious
Tumour is the squamous cell carcinoma that lining mucosal epithelium source occurs.Global disease burden (Global Burden of in 2016
Disease, GBD) recent statistics the result shows that, the whole world shares more than 130 ten thousand people and suffers from carcinoma of mouth, and death toll is about 17.6 ten thousand people,
In the high-incidence region of some carcinoma of mouth, annual new cases are up to the 1/4 of male malignancy.Morbidity of the carcinoma of mouth in China
Rate occupy the tenth of all malignant tumours, is not belonging to high-incidence cancer, but since population base of China is big, the absolute number of carcinoma of mouth
It measures still huge.In recent years, oral cavity cancer morbidity has the tendency that increasing and obvious rejuvenation, seriously endangers life and the life of patient
Deposit quality.Although there is the effects of clinic diagnosis of many tumours to make great progress, 5 years survival rates of carcinoma of mouth are always 50%
Left and right.So that patient is lost the organ function of some keys after carcinoma of mouth treatment, the quality of life of patient is caused to seriously affect.
Therefore, the early diagnosis of carcinoma of mouth has a very important significance.
Carcinoma of mouth is acknowledged as the process of a multistage, multi-step.Most carcinoma of mouth experienced normal tissue,
Precancerous lesion, precancerous condition, the development process of cancer.The key of carcinoma of mouth curative effect is early discovery, early diagnosis, early treatment.If
Early stage carcinoma of mouth, i.e. carcinoma in situ, early invasive carcinoma can be found early, can be obtained more satisfactory effect by operative treatment.
Therefore, early carcinomatous change how is found from a large amount of oral precancerous lesions, precancerous condition patient, improves the standard of carcinoma of mouth early diagnosis
True rate, this is extremely important to raising 5 annual survival rate of oral cancer patient and life quality.Currently, for detecting morning
Phase carcinoma of mouth method has very much, including clinical examination, histological examination, cytolgical examination, living tissue dyeing, immuning tissue
, Systems for optical inspection, hematology, imageology etc..However existing diagnostic method is limited to by traumatic, specific, sensibility etc.,
The diagnosis of carcinoma of mouth is caused especially to early diagnose effect not ideal enough.
Summary of the invention
In view of this, the present invention provides a kind of carcinoma of mouth diagnosis marker and its application, this kind of marker can be independent
Or two or more is combined to carry out the diagnosis of carcinoma of mouth.
In order to solve the above-mentioned technical problem, the invention discloses a kind of carcinoma of mouth diagnosis marker, which is
ADAM12、ADAMTS12、ALDH2、ALDH9A1、ARHGEF26、CAB39L、COL10A1、CTHRC1、CYP4B1、DFNA5、
One or more of EPHX2, HCG22, HLF, HOXC4, INHBA, RBP1, SH3BGRL2, SLITRK5, SSBP2 and XKR4.
Optionally, ADAM12, ADAMTS12, ALDH2, ALDH9A1, ARHGEF26, CAB39L, COL10A1, CTHRC1,
CYP4B1, DFNA5, EPHX2, HCG22, HLF, HOXC4, INHBA, RBP1, SH3BGRL2, SLITRK5, SSBP2 and XKR4's
Nucleotide probe sequences are respectively as shown in SEQ ID NO.1-SEQ ID NO.20.
The invention also discloses a kind of above-mentioned carcinoma of mouth diagnosis markers to prepare answering in carcinoma of mouth early diagnosis product
With the diagnostic products include the reagent for detecting one or more markers, and the reagent passes through detection subject oral cavity
The concentration of one or more markers described in tissue specimen judges whether subject suffers from carcinoma of mouth.
Optionally, the sample is oral cavity tissue.
Optionally, the reagent is when detecting one or more marker concentrations based on genechip detection or PCR
Required reagent.
Optionally, described marker ADAM12, ADAMTS12, COL10A1, CTHRC1, DFNA5, HOXC4, INHBA and
One or more of RBP1 is expressed in the cancerous tissue of oral cavity significantly to be increased compared with normal tissue expression.
Optionally, the marker ALDH2, ALDH9A1, ARHGEF26, CAB39L, CYP4B1, EPHX2, HCG22,
One or more of HLF, SH3BGRL2, SLITRK5, SSBP2 and XKR4 expressed in the cancerous tissue of oral cavity with normal tissue in
Expression is compared to significant decrease.
Optionally, the diagnostic products are kit, chip or detection platform.
The invention also discloses a kind of carcinoma of mouth early diagnosis kit, the kit is for detecting in carcinoma of mouth
ADAM12、ADAMTS12、ALDH2、ALDH9A1、ARHGEF26、CAB39L、COL10A1、CTHRC1、CYP4B1、DFNA5、
One or more of EPHX2, HCG22, HLF, HOXC4, INHBA, RBP1, SH3BGRL2, SLITRK5, SSBP2 and XKR4.
Compared with prior art, the present invention can be obtained including following technical effect：
The purpose of the present invention is the molecular indexes of screening carcinoma of mouth detection.By to carcinoma of mouth transcript profile in public database
With the integration and excavation of clinical data, combination difference expression is analyzed with ROC curve, and the present invention, which has screened 20, can be used for identifying
The molecular labeling of carcinoma of mouth.The area under the curve (AUC) of this 20 genes is all larger than 0.9, sensitivity with higher and special
Property, prompt its accuracy and susceptibility to reach 90% or more.Wherein the AUC of ADAM12, CAB39L, COL10A1 and HLF are greater than
0.95, the diagnosis of carcinoma of mouth can be directly used as.It is of the invention the result shows that can be using the expression value of these genes to carcinoma of mouth
Carry out molecular diagnosis.
Certainly, it implements any of the products of the present invention it is not absolutely required to while reaching all the above technical effect.
Detailed description of the invention
The drawings described herein are used to provide a further understanding of the present invention, constitutes a part of the invention, this hair
Bright illustrative embodiments and their description are used to explain the present invention, and are not constituted improper limitations of the present invention.In the accompanying drawings：
Detailed variation diagram that Fig. 1 is the oral cavity ADAM12 of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue and
Corresponding ROC curve；Wherein, A：Variation diagram of the ADAM12 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of ADAM12
Curve；
Fig. 2 is the oral cavity ADAMTS12 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and right
The ROC curve answered；Wherein, A：Variation diagram of the ADAMTS12 in oral cavity cancerous tissue and normal tissue；B：ADAMTS12 is corresponding
ROC curve；
Fig. 3 is the oral cavity ALDH2 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the ALDH2 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC curve of ALDH2；
Fig. 4 is the oral cavity ALDH9A1 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and right
The ROC curve answered；Wherein, A：Variation diagram of the ALDH9A1 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of ALDH9A1
Curve；
Fig. 5 is the oral cavity ARHGEF26 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and right
The ROC curve answered；Wherein, A：Variation diagram of the ARHGEF26 in oral cavity cancerous tissue and normal tissue；B：ARHGEF26 is corresponding
ROC curve；
Fig. 6 is the oral cavity CAB39L of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the CAB39L in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of CAB39L is bent
Line；
Fig. 7 is the oral cavity COL10A1 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and right
The ROC curve answered；Wherein, A：Variation diagram of the COL10A1 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of COL10A1
Curve；
Fig. 8 is the oral cavity CTHRC1 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the CTHRC1 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of CTHRC1 is bent
Line；
Fig. 9 is the oral cavity CYP4B1 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the CYP4B1 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of CYP4B1 is bent
Line；
Figure 10 is the oral cavity DFNA5 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the DFNA5 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC curve of DFNA5；
Figure 11 is the oral cavity EPHX2 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the EPHX2 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC curve of EPHX2；
Figure 12 is the oral cavity HCG22 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the HCG22 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC curve of HCG22；
Figure 13 is the oral cavity HLF of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the HLF in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC curve of HLF；
Figure 14 is the oral cavity HOXC4 of the present invention carcinoma marker in oral cavity cancerous tissue and variation diagram in normal tissue and corresponding
ROC curve；Wherein, A：Variation diagram of the HOXC4 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC curve of HOXC4；
Detailed variation diagram that Figure 15 is the oral cavity INHBA of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue and
Corresponding ROC curve；Wherein, A：Detailed variation diagram of the INHBA in oral cavity cancerous tissue and normal tissue；B：INHBA is corresponding
ROC curve；
Detailed variation diagram that Figure 16 is the oral cavity RBP1 of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue and
Corresponding ROC curve；Wherein, A：Detailed variation diagram of the RBP1 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of RBP1
Curve；
Figure 17 is detailed variation diagram of the oral cavity the SH3BGRL2 of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue
And corresponding ROC curve；Wherein, A：Detailed variation diagram of the SH3BGRL2 in oral cavity cancerous tissue and normal tissue；B：
The corresponding ROC curve of SH3BGRL2；
The detailed variation diagram that Figure 18 is the oral cavity SLITRK5 of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue with
And corresponding ROC curve；Wherein, A：Detailed variation diagram of the SLITRK5 in oral cavity cancerous tissue and normal tissue；B：SLITRK5
Corresponding ROC curve；
Detailed variation diagram that Figure 19 is the oral cavity SSBP2 of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue and
Corresponding ROC curve；Wherein, A：Detailed variation diagram of the SSBP2 in oral cavity cancerous tissue and normal tissue；B：SSBP2 is corresponding
ROC curve；
Detailed variation diagram that Figure 20 is the oral cavity XKR4 of the present invention carcinoma marker in oral cavity cancerous tissue and normal tissue and
Corresponding ROC curve；Wherein, A：Detailed variation diagram of the XKR4 in oral cavity cancerous tissue and normal tissue；B：The corresponding ROC of XKR4
Curve；
Specific embodiment
Carry out the embodiment that the present invention will be described in detail below in conjunction with embodiment, thereby to the present invention how application technology hand
Section solves technical problem and reaches the realization process of technical effect to fully understand and implement.
Embodiment 1：Carcinoma of mouth diagnosis marker：
Totally 20 kinds of carcinoma of mouth diagnosis marker provided by the invention, this kind of marker can individually or two or more
It combines to carry out the diagnosis of carcinoma of mouth；Including：ADAM12,ADAMTS12,ALDH2,ALDH9A1,ARHGEF26,CAB39L,
COL10A1、CTHRC1、CYP4B1、DFNA5、EPHX2、HCG22、HLF、HOXC4、INHBA、RBP1、SH3BGRL2、
SLITRK5, SSBP2 and XKR4.Its nucleotide probe sequences is as shown in SEQ IDNO.1-SEQ ID NO.20, specifically such as 1 institute of table
Show.
Table 1：The nucleotide probe sequences of 20 kinds of markers
Embodiment 2：The screening and identification of carcinoma of mouth diagnosis marker
Using genetic chip or PCR method come screening and appraisal mark object in the present invention, but the aspect identified might not
It is limited to above method, other methods such as chemical analysis method is applied equally to the screening of marker in identification.In the present invention
The screening of marker is illustrated in identification by taking lympha tumour tissue as an example：
1, data acquisition：
It is from downloading number in US National Biotechnology Information center gene expression data base (NCBI-GEO)
The transcript profile data of GSE42743, the data are the chip data of oral cancer patient's tumor tissues and normal oral tissue, data
It is linked as：https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi？Acc=GSE42743.From document
(Lohavanichbutr P,Méndez E,Holsinger FC,Rue TC et al.A 13-gene signature
prognostic of HPV-negative OSCC:discovery and external validation.Clin Cancer
Res 2013；19(5):1197-1203.) in obtain corresponding clinical data.Wherein carcinoma of mouth tumor tissues 74, normal mouth
Cavity tissue 29.
2, data prediction；
R language (v3.4.0 version, https are used first://www.r-project.org/) oligo program bag
(v1.38.0 version, http://www.bioconductor.org/packages/release/bioc/html/
Oligo.html the RNA algorithm in) is removed background noise, normalization and data summarization to all chips, and is expressed
Matrix.Download gene annotation platform GPL570 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi？
Acc=GPL570 gene annotation) is carried out to expression matrix, if multiple probes number a corresponding gene name in annotation procedure,
Using the expression mean value of these probes as the expression value of the gene.The probe of no gene name is removed simultaneously.
3, Differential expression analysis：
The difference expression gene between carcinoma of mouth tumor tissues and normal oral tissue is calculated using independent samples t test.
Multiple changes (fold-change, FC) calculation：Carcinoma of mouth expression of tumor tissue value/normal oral tissue expression value.Difference
The screening criteria of different expression conspicuousness is：|log2FC|≥log2Value≤0.05 1.2 and P.Screening is shown in carcinoma of mouth tumor tissues
Write the gene of differential expression.
4, receiver operating curves analyze：
Use pROC program bag (v1.12.1 version, the https in R language://web.expasy.org/pROC/) to every
The gene of a significant difference expression carries out area (AUC) under receiver operating curves (ROC) analysis and calculated curve, chooses AUC
Diagnosis index of the gene as carcinoma of mouth greater than 0.9.
5, the level of heretofore described one or two kinds of markers is measured in the tissue samples of subject：
By one or both of Samples subjects marker and one of 20 markers in control sample or a variety of
The level of marker compares, and the horizontal difference of one of Samples subjects or multiple markers indicates that the subject suffers from
There is carcinoma of mouth.
Wherein：The control sample can be normal oral tissue；The difference refer to subject's marker level with
Control group compare have conspicuousness (| log2FC|≥log2Value≤0.05 1.2 and P).
By the perspective study to oral cavity tumor tissue and normal oral tissue, each marker is in oral cancer patient
Variation and corresponding prediction curve under area ROC such as table 2.
Table 2：Area under variation and corresponding prediction curve of each marker in oral cancer patient
As seen from Table 2, area (AUC) is all larger than 0.9 under 20 all marker prediction curves.AUC value indicates mark
The predictive ability of object, AUC=1 is indicated can 100% precise Identification carcinoma of mouth.Therefore, the mouth that this patent provides as can be seen from Table 2
Chamber cancer diagnosis marker has high sensitivity, the high feature of accuracy.
Attached drawing 1-20A is shown in detailed variation of the 20 kinds of oral cavity carcinoma markers in oral cavity cancerous tissue and normal tissue.
The corresponding ROC curve of 20 kinds of oral cavity carcinoma markers is shown in attached drawing 1-20B.
From Fig. 1-Figure 20 it is found that this 20 carcinoma of mouth diagnosis markers have significantly in normal tissue and tumor tissues
Otherness, and there is preferable precision of prediction.
Above description has shown and described several preferred embodiments of invention, but as previously described, it should be understood that invention is not
It is confined to form disclosed herein, should not be regarded as an exclusion of other examples, and can be used for various other combinations, modification
And environment, and can be carried out within that scope of the inventive concept describe herein by the above teachings or related fields of technology or knowledge
Change.And changes and modifications made by those skilled in the art do not depart from the spirit and scope of invention, then it all should be in the appended power of invention
In the protection scope that benefit requires.
SEQUENCE LISTING
<110>Foshan Science &. Technology College's School of Stomatology
<120>Carcinoma of mouth diagnosis marker and its application
<130> 2018
<160> 30
<170> PatentIn version 3.3
<210> 1
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 1
TGGCTGCAAC TTAATGCTCT GATATGGCTT TTAGCATTTA TTATATGAAA ATAGCAGGGT 60
<210> 2
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 2
CAGACCTCCA GAATTCAAAA AATGCAACCA GCAGGCCTGC AAGAAAAGTG CCGATTTACT 60
<210> 3
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 3
AAATGATCCT TGCGTGCTGA ATATCTGAAA AGAGAAATTT TTCCTACAAA ATCTCTTGGG 60
<210> 4
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 4
CCAGTAACAT ACTTCTAGAG AACAGGAAAA GAGACTAGGA TAATACATCT TCCACACATT 60
<210> 5
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 5
TGGTAGAGTT CAGAAGGTGA GCTGTTGTTT TTCTAAACCT CTTCCCAGGA AGGGGACATT 60
<210> 6
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 6
CGGATGATGA GCAGTTCGCT GACGAGAAGA ACTACTTGAT TAAACAGATC CGAGACTTGA 60
<210> 7
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 7
ATACAGATTT GAGCTATCAG ACCAACAAAC CTTCCCCCTG AAAAGTGAGC AGCAACGTAA 60
<210> 8
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 8
CAAAGATGCG TTCAAATAGT GCTCTAAGAG TTTTGTTCAG TGGCTCACTT CGGCTAAAAT 60
<210> 9
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 9
ATCTCCTATA ATTGGCAAAC TTAAAAATGC AGCAGAAACT TACATTCCAA CCTTAGAGAC 60
<210> 10
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 10
TCTGTGCTTT AGGCAGAGAA CATTCATGAT GTCATATGTG AACTAGAAGT ACGTGTTACT 60
<210> 11
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 11
TGGCCTTACA CACATCTTGC ATGGATGGCA GCATTGTTCT GAAGGGGTTT GCAGAAAAAA 60
<210> 12
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 12
ACATATAAAC CCACAGCCAC TGCGGGTGGA AGGAGAAGGG CAGGGTGGAA AAAGTTTGAG 60
<210> 13
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 13
CACCATGATA TTGGTGGTAT TTATGCTGTT AAGTCCAAAC CTTTATCTGT CTGTTATTCT 60
<210> 14
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 14
TAGTGTCGAT GTGAAATGCC CCGTGATCAA TAATAAACCA GTGGATGTGA ATTAGTTTTA 60
<210> 15
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 15
AAACATCATC AAAAAGGACA TTCAGAACAT GATCGTGGAG GAGTGTGGGT GCTCATAGAG 60
<210> 16
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 16
AGGCAGTTGA GTGAAATGAA GAGCCACGTA GAGGATGGTG ACATAGCTGG GGCCCCAGCT 60
<210> 17
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 17
CAAATCTTCA GAGTTTTCCT AGTTCTTCTA GAAATACATG TCAGGTTTGT TTGTTCATCC 60
<210> 18
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 18
CCAAAATGAC ATGTTCATTT GACTACTATT GTAGCCGATT TTCGATTGTT TAACCAAACC 60
<210> 19
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 19
TGTGATCCAT TACCAAGTCT CCTCATGAAA ACCACAGTGA GTCAGCCCTT CACAGAACTA 60
<210> 20
<211> 60
<212> DNA
<213>Artificial sequence（Artificial sequence）
<400> 20
TCCCAGGAAA TCAAAGATGT AAATGATTAC TTTCATCCAT CCATTATAAC AAACCTGACC 60
Claims (9)
1. a kind of carcinoma of mouth diagnosis marker, which is characterized in that the marker be ADAM12, ADAMTS12, ALDH2,
ALDH9A1、ARHGEF26、CAB39L、COL10A1、CTHRC1、CYP4B1、DFNA5、EPHX2、HCG22、HLF、HOXC4、
One or more of INHBA, RBP1, SH3BGRL2, SLITRK5, SSBP2 and XKR4.
2. carcinoma of mouth diagnosis marker according to claim 1, which is characterized in that ADAM12, ADAMTS12, ALDH2,
ALDH9A1、ARHGEF26、CAB39L、COL10A1、CTHRC1、CYP4B1、DFNA5、EPHX2、HCG22、HLF、HOXC4、
The nucleotide probe sequences of INHBA, RBP1, SH3BGRL2, SLITRK5, SSBP2 and XKR4 are respectively such as SEQ ID NO.1-SEQ
Shown in ID NO.20.
3. carcinoma of mouth diagnosis marker according to claim 1 prepares the application in carcinoma of mouth early diagnosis product, special
Sign is that the diagnostic products include the reagent for detecting one or more markers, and the reagent passes through detection subject
The concentration of one or more markers described in oral cavity tissue sample judges whether subject suffers from carcinoma of mouth.
4. application according to claim 3, which is characterized in that the sample is oral cavity tissue.
5. application according to claim 3, which is characterized in that the reagent is detected based on genechip detection or PCR
Required reagent when one or more marker concentrations.
6. application according to claim 3, which is characterized in that the marker ADAM12, ADAMTS12, COL10A1,
One or more of CTHRC1, DFNA5, HOXC4, INHBA and RBP1 are expressed in the cancerous tissue of oral cavity and normal oral tissue
Middle expression, which is compared, significantly increases.
7. application according to claim 3, which is characterized in that the marker ALDH2, ALDH9A1, ARHGEF26,
One or more of CAB39L, CYP4B1, EPHX2, HCG22, HLF, SH3BGRL2, SLITRK5, SSBP2 and XKR4 are in mouth
Expression significantly reduces compared with expressing in normal oral tissue in chamber cancerous tissue.
8. the application according to any one of claim 3-7, which is characterized in that the diagnostic products are kit, chip
Or detection platform.
9. a kind of carcinoma of mouth early diagnosis kit, which is characterized in that the kit be used to detect ADAM12 in carcinoma of mouth,
ADAMTS12、ALDH2、ALDH9A1、ARHGEF26、CAB39L、COL10A1、CTHRC1、CYP4B1、DFNA5、EPHX2、
One or more of HCG22, HLF, HOXC4, INHBA, RBP1, SH3BGRL2, SLITRK5, SSBP2 and XKR4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811172243.8A CN108866200A (en) | 2018-10-08 | 2018-10-08 | Carcinoma of mouth diagnosis marker and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811172243.8A CN108866200A (en) | 2018-10-08 | 2018-10-08 | Carcinoma of mouth diagnosis marker and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108866200A true CN108866200A (en) | 2018-11-23 |
Family
ID=64324967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811172243.8A Withdrawn CN108866200A (en) | 2018-10-08 | 2018-10-08 | Carcinoma of mouth diagnosis marker and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108866200A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110846417A (en) * | 2019-12-10 | 2020-02-28 | 湖南省肿瘤医院 | Diagnosis and treatment marker for head and neck squamous cell carcinoma |
| CN111635939A (en) * | 2020-06-01 | 2020-09-08 | 青岛大学附属医院 | Product for detecting RBP1 gene or protein and application |
| CN111868261A (en) * | 2017-12-20 | 2020-10-30 | 美国控股实验室公司 | Compositions and methods for detecting head and neck cancer |
-
2018
- 2018-10-08 CN CN201811172243.8A patent/CN108866200A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111868261A (en) * | 2017-12-20 | 2020-10-30 | 美国控股实验室公司 | Compositions and methods for detecting head and neck cancer |
| US11933784B2 (en) | 2017-12-20 | 2024-03-19 | Laboratory Corporation Of America Holdings | Compositions and methods to detect head and neck cancer |
| CN110846417A (en) * | 2019-12-10 | 2020-02-28 | 湖南省肿瘤医院 | Diagnosis and treatment marker for head and neck squamous cell carcinoma |
| CN111635939A (en) * | 2020-06-01 | 2020-09-08 | 青岛大学附属医院 | Product for detecting RBP1 gene or protein and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108866200A (en) | Carcinoma of mouth diagnosis marker and its application | |
| CN107326066A (en) | The urine markers detected for carcinoma of urinary bladder | |
| Osmulski et al. | Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer | |
| JP2007512801A (en) | Biomarker panel for colorectal cancer | |
| WO2022012280A1 (en) | Peripheral blood tcr marker for lung cancer, detection kit therefor and application thereof | |
| Liang et al. | Label-free distinction between p53+/+ and p53-/-colon cancer cells using a graphene based SERS platform | |
| WO2022012284A1 (en) | Peripheral blood tcr marker for melanoma, and detection kit and use thereof | |
| CN104046624B (en) | Gene and application thereof for lung cancer for prognosis | |
| CN108531597A (en) | A kind of detection kit for oral squamous cell carcinomas early diagnosis | |
| CN113528672A (en) | Biomarker combination for early screening of bladder cancer, kit and application | |
| Shao et al. | A triple-classification radiomics model for the differentiation of pleomorphic adenoma, Warthin tumour, and malignant salivary gland tumours on the basis of diffusion-weighted imaging | |
| CN116083584A (en) | Plasma miRNA markers for assessing risk of non-small cell lung cancer, screening method and application thereof | |
| CN108559777A (en) | A kind of New molecular marker and its application in preparing for the kit of clear cell carcinoma of kidney diagnosis and prognosis | |
| CN101307361A (en) | Method for identifying miRNA in blood serum of patient with lung cancer by Solexa technology | |
| Song et al. | The identification and validation of a robust immune-associated gene signature in cutaneous melanoma | |
| KR102271315B1 (en) | Method for prognosis of breast cancer using ribosomal protein from artificial intelligence | |
| Bhat et al. | Application of HPLC combined with laser induced fluorescence for protein profile analysis of tissue homogenates in cervical cancer | |
| EP1934367A4 (en) | Molecular method for diagnosis of prostate cancer | |
| CN109735619A (en) | Molecular marker relevant to non-small cell lung cancer prognosis and its application | |
| KR102271313B1 (en) | Method for prognosis of breast cancer using mitochondria ribosomal protein artificial intelligence | |
| Scarlett et al. | Classification of pancreatic cystic lesions using SELDI‐TOF mass spectrometry | |
| CN108546761A (en) | A kind of detection kit for oral squamous cell carcinomas lymphatic metastasis prediction | |
| CN107904309B (en) | It is a kind of for diagnose indication three negative type breast cancers Bone tumours gene diagnosis kit | |
| CN109207591A (en) | Women population mesorrhine NK/T cell lymphoma diagnosis marker and its application | |
| CN106636375A (en) | Marker miR-126-3P for HER-2 positive breast cancer tissue, and application and diagnosis kit of marker miR-126-3P |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Dahai Inventor after: Li Wenxing Inventor after: Yang Hua Inventor after: Jiao Wenqiao Inventor after: Yang Shuting Inventor after: Liu Fang Inventor after: Yang Anping Inventor before: Liu Dahai Inventor before: Li Wenxing Inventor before: Yang Shuting Inventor before: Liu Fang Inventor before: Yang Anping |
|
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181123 |